Shantha Biotechnics is a biotechnology company based in Hyderabad, Telangana, India. The company was founded in 1993 and is focused on developing and manufacturing vaccines and biopharmaceuticals for various diseases.
Shantha Biotechnics has developed a number of vaccines, including Shanvac-B, a vaccine for hepatitis B, and Shan5, a combination vaccine for diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type B. The company has also developed a range of biopharmaceuticals for the treatment of cancer, autoimmune diseases, and other conditions.
In 2008, Shantha Biotechnics was acquired by Sanofi Pasteur, the vaccine division of French pharmaceutical company Sanofi. As part of Sanofi Pasteur, Shantha Biotechnics has continued to develop and manufacture vaccines and biopharmaceuticals for global markets.
Shantha Biotechnics has received several awards and recognition for its contributions to the field of biotechnology and healthcare, including the National Award for R&D in Industry by the Government of India in 2007.
Shanta Biotechnics, Hyderabad is the first Indian company to launch an r-DNA vaccine in 1997.
With its research-driven scientific ethos Shantha Biotechnics continues to push boundaries and transcend limitations.
H.No.5-10-173, 3rd & 4th Floors,
Vasantha Chambers,
Fateh Maidan Road, Basheerbagh,
Hyderabad - 500 004.
A.P., INDIA.
Phone: +91 40 23234136.
Fax: +91 40 23234103.
E-mail: info@shanthabiotech.co.in